LONDON, ON, Oct. 13, 2023 /PRNewswire/ -- Alimentiv Inc. ('Alimentiv'), a leading Contract Research Organization focused on GI-related therapeutics, is pleased to announce the addition of new scientific advisors to its scientific advisory board.  The advisors are internationally recognized experts in designing and conducting clinical research in Inflammatory Bowel Disease.  Their contributions to the field have been essential in progressing the development of novel therapies in IBD and improving patient outcomes..

伦敦，2023年10月13日/PRNewswire/-Alimentiv Inc.（'Alimentiv'），一家专注于GI相关治疗的领先合同研究组织，很高兴地宣布为其科学顾问增加新的科学顾问顾问委员会。顾问是设计和开展炎症性肠病临床研究的国际公认专家。他们对该领域的贡献对于促进IBD新疗法的开发和改善患者预后至关重要。。

Continue Reading

继续阅读

Dr. Bruce Sands

布鲁斯·桑兹博士

Dr./Prof. Remo Panaccione

Remo Panaccione博士/教授

Alimentiv Inc. Logo

Alimentiv Inc. Logo

Dr./Prof. Remo Panaccione is a Professor of Medicine and the Director of the Inflammatory Bowel Disease Unit at the University of Calgary, Alberta, Canada. He serves as the Dean of MD Admissions and Director of the IBD Fellowship Program. He holds the Crohn's Colitis Canada Endowed Research Chair in Inflammatory Bowel Disease and is an executive member of the IOIBD..

Remo Panaccione博士/教授是加拿大艾伯塔省卡尔加里大学医学教授和炎症性肠病科主任。他担任医学博士招生院长和IBD奖学金项目主任。他担任克罗恩结肠炎加拿大资助的炎症性肠病研究主席，并且是IOIBD的执行成员。。

Dr. Panaccione is the 2020 Crohn's Colitis Canada Outstanding Physician of the Year and is recognized as a 2020-23 Clarivate Research Scholar for being cited in the top 1% of researchers worldwide. He has co-authored over 350 manuscripts, 20 book chapters, and 625 abstracts, including publications in journals such as the New England Journal of Medicine, Lancet, JAMA, Nature, and Annals of Internal Medicine. .

Panaccione博士是2020年克罗恩结肠炎加拿大杰出医师，被公认为2020-23年度Clarivate研究学者，被评为全球研究人员前1%。他共撰写了350多篇手稿，20章书籍和625篇摘要，其中包括新英格兰医学杂志，柳叶刀，JAMA，自然和内科年鉴等期刊的出版物。 .

Prof. Panaccione's primary research interest is designing and implementing clinical trials. He has been the principal investigator on several studies evaluating the efficacy and safety of new therapeutic agents in patients with IBD.Dr. Bruce Sands, MD, MS, is the Dr. Burrill B. Crohn Professor of Medicine at the Icahn School of Medicine at Mount Sinai, New York, NY.

Panaccione教授的主要研究兴趣是设计和实施临床试验。他一直是几项评估IBD患者新治疗药物疗效和安全性的研究的首席研究员.Bruce Sands博士，医学博士，硕士，是伊坎医学院的Burrill B.Crohn博士医学教授。纽约州西奈山。

Dr. Sands is widely recognized for his clinical investigations of new therapeutics for inflammatory bowel diseases and has published over 275 original manuscripts. He was the lead investigator of the landmark studies ACCENT 2, UNIFI, and VARSITY, published in the New England Journal of Medicine, and SEAVUE, published in the Lancet.

Sands博士因其对炎症性肠病新疗法的临床研究而得到广泛认可，并发表了超过275篇原创手稿。他是发表在《新英格兰医学杂志》上的具有里程碑意义的研究口音2，UNIFI和VARSITY以及发表在《柳叶刀》上的SEAVUE的首席研究员。

Dr. Bruce Sands serves as a paid consultant for Alimentiv.'We are committed to the leadership in GI research and proud to work with industry leaders whose research is instrumental in progressing clinical development programs and treatments for patients living with GI-related illnesses,' said Dr. Gabriela Radulescu, Vice President, Medical Research and Development..

Bruce Sands博士担任Alimentiv的付费顾问我们致力于GI研究领域的领导地位，并自豪地与行业领导者合作，他们的研究有助于推进GI相关疾病患者的临床开发计划和治疗，“医学研究副总裁Gabriela Radulescu博士说。发展。。

About Alimentiv Inc.

关于Alimentiv Inc。

Alimentiv is a global gastroenterology-focused contract research organization (CRO) providing clinical trials, central image management, precision medicine, and real-world evidence services to the pharmaceutical and biotechnology industries. Headquartered in London, Ontario, Alimentiv employs more than 500 people across its operations in Canada, the United States, Europe, Asia-Pacific, and Latin America.

Alimentiv是一家以全球胃肠病学为重点的合同研究组织（CRO），为制药和生物技术行业提供临床试验，中心图像管理，精准医学和现实证据服务。Alimentiv总部设在安大略省伦敦，在加拿大，美国，欧洲，亚太地区和拉丁美洲的运营中雇用了500多名员工。

The organization's unique model combines the efforts of internationally recognized academic researchers and operational experts to offer integrated solutions to customers. Over the past 20 years, Alimentiv has become a recognized expert in clinical trial design, central image management solutions, outcome measure development, and precision medicine for drug development in GI.

该组织独特的模式结合了国际公认的学术研究人员和运营专家的努力，为客户提供综合解决方案。在过去的20年中，Alimentiv已成为GI临床试验设计，中心图像管理解决方案，结果测量开发和精准药物开发方面的公认专家。

Today, Alimentiv provides services in more than 50 countries worldwide, collaborates with leading universities and academic institutions across the globe, and works with many leading pharmaceutical and biotechnology organizations to bring new and improved treatment options to patients. Alimentiv is committed to investment in medical research and development, focusing on identifying barriers to drug development and pursuing solutions that advance GI research.

今天，Alimentiv在全球50多个国家提供服务，与全球领先的大学和学术机构合作，并与许多领先的制药和生物技术组织合作，为患者带来新的和改进的治疗方案。Alimentiv致力于医学研究和开发投资，重点是确定药物开发的障碍并寻求推进GI研究的解决方案。

The research findings are operationalized into an efficient clinical trial methodology for clients that aligns with emerging regulatory standards. In collaboration with leading experts, Alimentiv has pioneered the development, validation, and standardization of outcome measures and technology, shaping the evolving clinical trial landscape for multiple indications and providing meaningful long-term consequences for patients, their treatment, and society.

研究结果可用于符合新兴监管标准的客户的有效临床试验方法。Alimentiv与领先的专家合作，开创了结果测量和技术的开发，验证和标准化，为多种适应症塑造了不断发展的临床试验环境，并为患者，他们的治疗和社会提供了有意义的长期后果。

For more information, visit: www.alimentiv.comPhoto - https://mma.prnewswire.com/media/22458.

For more information, visit: www.alimentiv.comPhoto - https://mma.prnewswire.com/media/22458.